Request Trial
John Squires, who delivered his first public remarks in Washington, DC after becoming USPTO president
EPNAC.com
1 November 2025NewsAmericasSarah Speight

Squires: ‘Inherited patent backlog was an absolute dumpster fire’

In his first public remarks since becoming the USPTO director, a bombastic John Squires promises an agency “in overdrive” that's doubling down on AI, reports Sarah Speight.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Week Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com 


More on this story

Americas
Explaining genetically engineered rodents to a jury—and ultimately beating Amgen
10 July 2026   Harbour’s trial counsel shares the strategy behind the company’s $20m win, revealing how a highly technical patent dispute became a case about credibility as much as science.
Americas
Exelixis opens two-front patent dispute over Cabometyx copies
9 July 2026   Separate lawsuits target Indian and Taiwanese pharma companies as Exelixis seeks to keep rival cabozantinib products off the US market until key patents expire.
Americas
LSD trade secrets suit over clinical trail info thrown out by judge
2 July 2026   A federal court has ruled in a dispute between a clinical trial technology company and a psychedelic drug developer over allegations of trade secret misuse during a bidding process.


Editor's picks

What’s at stake in Australia’s biggest pharma patent appeal in years?
Pharma
What’s at stake in Australia’s biggest pharma patent appeal in years?
1 July 2026

Editor's picks

Pharma
What’s at stake in Australia’s biggest pharma patent appeal in years?
1 July 2026
Biotech
Novartis and Eli Lilly sign separate $1.9bn novel drug deals
25 June 2026
Biotech
Insilico lands potential $2.5bn AI biotech partnership
22 June 2026
Pharma
US life sciences damages averaged $33.5m between 2019-2025
18 June 2026
Americas
Hikma v Amarin: Six takeaways from the pivotal ruling
9 June 2026
Americas
Takeda to appeal $885m jury verdict over ‘pay-for-delay’ scheme
19 May 2026

More features

Sanofi launches mRNA lawsuits on Moderna and Pfizer
UK-Switzerland strike trade deal with first-of-its-kind pharma rules
IP Federation elects Philips licensing leader as new president
Interview: How BlueRock Therapeutics is layering IP in stem cell therapies
Explaining genetically engineered rodents to a jury—and ultimately beating Amgen
Exelixis opens two-front patent dispute over Cabometyx copies
UPC upholds injunction in Invisalign maker’s software dispute with rival
BioNTech and Pfizer secure big European win over mRNA patent